Tag: Generics

By Brendan Coffman, Thu Hoang & Nathan Mendelsohn (Wilson Sonsini Goodrich & Rosati)1   On January 27, 2020, the Federal Trade Commission (“FTC”) and the State...

The generic industry lobby, Association for Accessible Medicines (“AAM”), often represents the public interest. In the pharmaceutical industry, it challenges brand drug companies’ anticompetitive...

This piece discusses pharmaceutical product reformulations and product hopping strategies, along with the impact that antitrust scrutiny may have on innovation incentives. The main...

By James Killick, Marc Israel, Jérémie Jourdan & Aqeel Kadri (White & Case LLP)1 On January 30, 2020 (just sneaking in before Brexit), the European...

Maria José Schmidt-Kessen (Copenhagen Business School)1   Introduction While we are still awaiting the judgments in the pending appeals on pay-for-delay settlements in Lundbeck2 and Servier,3 the...

Jan Blockx (University of Antwerp)1 Introduction Twelve years ago, on January 15, 2008, the European Commission used its power to conduct unannounced inspections in a sector...

By William S. Comanor & Diana L. Moss -  The proposed Teva-Allergan merger joins the largest generic pharmaceutical company in the world, Teva Pharmaceuticals, with an...

With the Supreme Court ruling on Obama Care, much of the business world is focused on healthcare. In honor of that attention, we decided...

William Michael, Aidan Synnott, Sep 24, 2009 During his campaign for the Presidency, then-Senator Barack Obama promised that he would direct his administration to reinvigorate...

Kevin Noonan, Sep 30, 2013 In June, the Supreme Court ruled 5-3 in favor of the Federal Trade Commission in FTC v. Actavis, Inc. Writing...